MNOV – Medicinova Inc
Float Short %
0.48
Margin Of Safety %
Put/Call OI Ratio
0.16
EPS Next Q Diff
-0.01
EPS Last/This Y
-0.27
EPS This/Next Y
0.18
Price
1.5
Target Price
10
Analyst Recom
1
Performance Q
4.17
Upside
-308.0%
Beta
0.57
Ticker: MNOV
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-01-23 | MNOV | 1.87 | 0.16 | 0.00 | 108 |
| 2026-01-26 | MNOV | 1.875 | 0.16 | 0.00 | 108 |
| 2026-01-27 | MNOV | 1.835 | 0.16 | 0.00 | 108 |
| 2026-01-28 | MNOV | 1.79 | 0.16 | 0.00 | 108 |
| 2026-01-29 | MNOV | 1.76 | 0.16 | 0.00 | 108 |
| 2026-01-30 | MNOV | 1.74 | 0.16 | 0.00 | 108 |
| 2026-02-02 | MNOV | 1.67 | 0.16 | 0.00 | 110 |
| 2026-02-03 | MNOV | 1.64 | 0.16 | 0.00 | 110 |
| 2026-02-04 | MNOV | 1.635 | 0.16 | 0.00 | 110 |
| 2026-02-05 | MNOV | 1.62 | 0.13 | 0.00 | 130 |
| 2026-02-06 | MNOV | 1.625 | 0.13 | 0.00 | 130 |
| 2026-02-09 | MNOV | 1.6491 | 0.13 | 0.00 | 130 |
| 2026-02-10 | MNOV | 1.635 | 0.13 | 0.00 | 130 |
| 2026-02-11 | MNOV | 1.62 | 0.13 | 0.00 | 130 |
| 2026-02-12 | MNOV | 1.57 | 0.15 | 999.99 | 118 |
| 2026-02-13 | MNOV | 1.49 | 0.16 | 999.99 | 119 |
| 2026-02-17 | MNOV | 1.605 | 0.16 | 999.99 | 119 |
| 2026-02-18 | MNOV | 1.58 | 0.16 | 999.99 | 119 |
| 2026-02-20 | MNOV | 1.48 | 0.16 | 999.99 | 119 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-01-23 | MNOV | 1.87 | -58.3 | - | -0.50 |
| 2026-01-26 | MNOV | 1.87 | -58.3 | - | -0.50 |
| 2026-01-27 | MNOV | 1.84 | -58.3 | - | -0.50 |
| 2026-01-28 | MNOV | 1.76 | -58.3 | - | -0.50 |
| 2026-01-29 | MNOV | 1.75 | -58.3 | - | -0.50 |
| 2026-01-30 | MNOV | 1.73 | -58.3 | - | -0.50 |
| 2026-02-02 | MNOV | 1.66 | -58.3 | - | -0.50 |
| 2026-02-03 | MNOV | 1.64 | -58.3 | - | -0.50 |
| 2026-02-04 | MNOV | 1.63 | -58.3 | - | -0.50 |
| 2026-02-05 | MNOV | 1.63 | -58.3 | - | -0.50 |
| 2026-02-06 | MNOV | 1.62 | -58.3 | - | -0.50 |
| 2026-02-09 | MNOV | 1.65 | -58.3 | - | -0.50 |
| 2026-02-10 | MNOV | 1.63 | -58.3 | - | -0.50 |
| 2026-02-11 | MNOV | 1.60 | -58.3 | - | -0.50 |
| 2026-02-12 | MNOV | 1.57 | -58.3 | - | -0.50 |
| 2026-02-13 | MNOV | 1.50 | -58.3 | - | -0.50 |
| 2026-02-17 | MNOV | 1.61 | -58.3 | - | -0.50 |
| 2026-02-18 | MNOV | 1.58 | -58.3 | - | -0.50 |
| 2026-02-19 | MNOV | 1.55 | -58.3 | - | -0.50 |
| 2026-02-20 | MNOV | 1.50 | -58.3 | - | -0.50 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-01-23 | MNOV | 0.00 | -0.11 | 0.60 |
| 2026-01-26 | MNOV | 0.00 | -0.11 | 0.60 |
| 2026-01-27 | MNOV | 0.00 | -0.11 | 0.60 |
| 2026-01-28 | MNOV | 0.00 | -0.11 | 0.58 |
| 2026-01-29 | MNOV | 0.00 | -0.11 | 0.58 |
| 2026-01-30 | MNOV | 0.00 | -0.11 | 0.58 |
| 2026-02-02 | MNOV | 0.00 | -0.11 | 0.58 |
| 2026-02-03 | MNOV | 0.00 | -0.11 | 0.58 |
| 2026-02-04 | MNOV | 0.00 | -0.11 | 0.58 |
| 2026-02-05 | MNOV | 0.00 | -0.11 | 0.58 |
| 2026-02-06 | MNOV | 0.00 | -0.11 | 0.58 |
| 2026-02-10 | MNOV | 0.00 | -0.13 | 0.58 |
| 2026-02-11 | MNOV | 0.00 | -0.13 | 0.48 |
| 2026-02-12 | MNOV | 0.00 | -0.13 | 0.48 |
| 2026-02-13 | MNOV | 0.00 | -0.13 | 0.48 |
| 2026-02-17 | MNOV | 0.00 | -0.01 | 0.48 |
| 2026-02-18 | MNOV | 0.00 | -0.01 | 0.48 |
| 2026-02-19 | MNOV | 0.00 | -0.01 | 0.48 |
| 2026-02-20 | MNOV | 0.00 | -0.01 | 0.48 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.06
Avg. EPS Est. Current Quarter
-0.12
Avg. EPS Est. Next Quarter
-0.07
Insider Transactions
Institutional Transactions
-0.01
Beta
0.57
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
22
Growth Score
18
Sentiment Score
56
Actual DrawDown %
86.1
Max Drawdown 5-Year %
-87.1
Target Price
10
P/E
Forward P/E
PEG
P/S
283.55
P/B
1.67
P/Free Cash Flow
EPS
-0.24
Average EPS Est. Cur. Y
-0.5
EPS Next Y. (Est.)
-0.32
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-4656.65
Relative Volume
0.3
Return on Equity vs Sector %
-56.3
Return on Equity vs Industry %
-38.9
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
MediciNova, Inc.Sector: Healthcare
Industry: Biotechnology
Employees:
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2b/3 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. It is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. The company has a license agreement with Kyorin Pharmaceuticals for the development and commercialization of MN-166 and MN-001. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
stock quote shares MNOV – Medicinova Inc Stock Price stock today
news today MNOV – Medicinova Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch MNOV – Medicinova Inc yahoo finance google finance
stock history MNOV – Medicinova Inc invest stock market
stock prices MNOV premarket after hours
ticker MNOV fair value insiders trading